Islet β-cell-produced NUCB2/nesfatin-1 maintains insulin secretion and glycemia along with suppressing UCP-2 in β-cells

The journal of physiological sciences

article

Yifei Yang¹  Boyang Zhang¹  Masanori Nakata¹  Jun Nakae⁵  Masatomo Mori⁶  Toshihiko Yada¹ 

[1] Division of Integrative Physiology, Department of Physiology, Jichi Medical University School of Medicine;Division of Integrative Physiology, Kansai Electric Power Medical Research Institute;Division of System Neuroscience, Kobe University Graduate School of Medicine;Department of Physiology, Wakayama Medical University School of Medicine;Center for Medical Science, International University of Health and Welfare;Kitakanto Molecular Novel Research Institute for Obesity and Metabolism

关键词: NUCB2;    Nesfatin-1;    Insulin secretion;    Islet β-cell;    MIN6;    UCP-2;   

DOI  :  10.1007/s12576-019-00689-2

来源: Springer

【 摘 要 】

Nesfatin-1 is a hypothalamic anorexigenic peptide processed from nucleobindin 2 (NUCB2). Central and peripheral administration of NUCB2/nesfatin-1 enhances glucose metabolism and insulin release. NUCB2/nesfatin-1 is also localized in pancreatic islets, while its function remains unknown. To explore the role of pancreatic β-cell-produced NUCB2/nesfatin-1, we developed pancreatic β-cell-specific NUCB2 knockout (βNUCB2 KO) mice and NUCB2 gene knockdown (shNUCB2) MIN6 β-cell line. In βNUCB2 KO mice, casual blood glucose was elevated from 12 weeks of age. In a glucose tolerance test at 12 weeks, insulin secretion at 15 min was reduced and blood glucose at 2 h increased in βNUCB2 KO mice fasted 8 h. In islets isolated from βNUCB2 KO mice, high glucose-stimulated insulin secretion (GSIS) was impaired. In shNUCB2 MIN6 cells, GSIS was reduced and UCP-2 mRNA expression was elevated. These results show impaired GSIS possibly associated with UCP-2 overexpression in NUCB2-silenced β-cells, suggesting that β-cell-produced NUCB2/nesfatin-1 maintains GSIS and thereby glycemia.

【 授权许可】

Unknown